|
| Index | - | P/E | - | EPS (ttm) | -0.64 | Insider Own | 18.00% | Shs Outstand | 32.48M | Perf Week | 25.24% |
| Market Cap | 625.24M | Forward P/E | - | EPS next Y | -1.75 | Insider Trans | 0.00% | Shs Float | 2.17M | Perf Month | -10.05% |
| Income | -22.20M | PEG | - | EPS next Q | -1.46 | Inst Own | 38.40% | Short Float | 24.39% | Perf Quarter | - |
| Sales | - | P/S | - | EPS this Y | -38.40% | Inst Trans | - | Short Ratio | 2.63 | Perf Half Y | - |
| Book/sh | - | P/B | - | EPS next Y | - | ROA | - | Target Price | - | Perf Year | - |
| Cash/sh | 2.59 | P/C | 7.43 | EPS next 5Y | 38.00% | ROE | - | 52W Range | 14.00 - 23.10 | Perf YTD | 10.63% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -16.67% | Beta | - |
| Dividend % | - | Quick Ratio | 20.00 | Sales past 5Y | - | Gross Margin | - | 52W Low | 37.50% | ATR | 1.87 |
| Employees | 31 | Current Ratio | 20.00 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 57.93 | Volatility | 11.55% 9.62% |
| Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.88 | Prev Close | 18.14 |
| Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 201.29K | Price | 19.25 |
| Recom | - | SMA20 | 8.40% | SMA50 | 6.58% | SMA200 | 6.58% | Volume | 178,029 | Change | 6.12% |
 | ||||||||||||||||||||||||
| ||||||||||||||||||||||||
|
||||||||||||||||||||||||
| ||||||||||||||||||||||||
|
||||||||||||||||||||||||
| ||||||||||||||||||||||||
| Cyteir Therapeutics, Inc. operates as a clinical-stage oncology company that develops novel therapeutics based on the biology of DNA repair for the treatment of cancer and synthetic lethality therapeutics for autoimmune diseases. The company engages in manufacturing therapeutics that provide precision targeting of key DNA repair factors to induce diseased cells to self-destruct by DNA damage overload and uses an integrated drug development platform that modulates the imbalance between DNA damage and repair for the therapeutic effect to deliver a pipeline of small molecule therapeutics with a range of potential disease state applications. It provides CYT-0851, an oral small-molecule inhibitor of RAD51-mediated DNA repair. It focuses on providing treatments for a range of hematological malignancies, solid tumors, and chronic autoimmune disorders. The company was incorporated in 2012 and is based in Lexington, Massachusetts. | ||||||||||||||||||||||||
| ||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite